Translational Models in Glioma Immunotherapy Research

Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed feature...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Alexander L., Wu, Janet Y., Lee, Si Yeon, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296936/
https://www.ncbi.nlm.nih.gov/pubmed/37366911
http://dx.doi.org/10.3390/curroncol30060428
_version_ 1785063765572583424
author Ren, Alexander L.
Wu, Janet Y.
Lee, Si Yeon
Lim, Michael
author_facet Ren, Alexander L.
Wu, Janet Y.
Lee, Si Yeon
Lim, Michael
author_sort Ren, Alexander L.
collection PubMed
description Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research.
format Online
Article
Text
id pubmed-10296936
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102969362023-06-28 Translational Models in Glioma Immunotherapy Research Ren, Alexander L. Wu, Janet Y. Lee, Si Yeon Lim, Michael Curr Oncol Review Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research. MDPI 2023-06-11 /pmc/articles/PMC10296936/ /pubmed/37366911 http://dx.doi.org/10.3390/curroncol30060428 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ren, Alexander L.
Wu, Janet Y.
Lee, Si Yeon
Lim, Michael
Translational Models in Glioma Immunotherapy Research
title Translational Models in Glioma Immunotherapy Research
title_full Translational Models in Glioma Immunotherapy Research
title_fullStr Translational Models in Glioma Immunotherapy Research
title_full_unstemmed Translational Models in Glioma Immunotherapy Research
title_short Translational Models in Glioma Immunotherapy Research
title_sort translational models in glioma immunotherapy research
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296936/
https://www.ncbi.nlm.nih.gov/pubmed/37366911
http://dx.doi.org/10.3390/curroncol30060428
work_keys_str_mv AT renalexanderl translationalmodelsingliomaimmunotherapyresearch
AT wujanety translationalmodelsingliomaimmunotherapyresearch
AT leesiyeon translationalmodelsingliomaimmunotherapyresearch
AT limmichael translationalmodelsingliomaimmunotherapyresearch

Ejemplares similares